Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OMCL INVESTOR ALERT: Hagens Berman Alerts Omnicell (OMCL) Investors to Investigation of Possible Disclosure Violations

OMCL

SAN FRANCISCO, July 11, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, alerts investors in automated medication supply manufacturer Omnicell, Inc. (NASDAQ: OMCL) to the firm's investigation of possible securities law violations.

Hagens Berman Sobol Shapiro LLP (PRNewsfoto/Hagens Berman Sobol Shapiro LLP)

If you purchased or otherwise acquired OMCL securities on or before July 10, 2019 and suffered losses or have information that may assist the firm's investigation contact Hagens Berman:

https://www.hbsslaw.com/investor-fraud/omnicell

or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing

OMCL@hbsslaw.com.

On July 10, 2019, GlassHouse Research published a detailed report alleging the Company obfuscated its financials over the past two years "by using a variety of accounting gimmicks."  After analyzing Omnicell's accounts receivable (AR), inventory, and capitalized expense diagnostics, GlassHouse concluded that Omnicell has prematurely recognized over $38 million in sales revenue, failed to write-off over $23 million in obsolete inventory, and has misclassified and accelerated the capitalization of over $38 million in expenses.

On this news, the Company's share price plummeted 13% on July 11, 2019, thereby injuring Omnicell shareholders.

"We're focused on investors' losses and whether the Company has misled the market by manipulating its reported financials in violation of Generally Accepted Accounting Principles," said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Omnicell should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email OMCL@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm representing investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes is located at hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/omcl-investor-alert-hagens-berman-alerts-omnicell-omcl-investors-to-investigation-of-possible-disclosure-violations-300883878.html

SOURCE Hagens Berman Sobol Shapiro LLP



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today